Key Points
- Director David Pyott sold 3,830 shares of Alnylam Pharmaceuticals at an average price of $299.18, a transaction worth about $1.15 million. After the sale, he retained 1,582 shares, and the move was made under a pre-arranged Rule 10b5-1 plan.
- Alnylam shares were up 2.3% in Thursday trading, opening at $292.58. The stock has a market cap of $39.06 billion and remains well below its 52-week high of $495.55.
- The company posted strong quarterly results, reporting EPS of $1.99 versus the $0.87 consensus and revenue of $1.17 billion, up 96.4% year over year. Analysts currently rate the stock a “Moderate Buy” with a consensus price target of $463.13.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) Director David Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company's stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alnylam Pharmaceuticals Trading Up 2.3%
NASDAQ ALNY opened at $292.58 on Thursday. The company has a market cap of $39.06 billion, a price-to-earnings ratio of 79.94 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a 52 week low of $283.10 and a 52 week high of $495.55. The business has a 50 day moving average price of $308.26 and a 200-day moving average price of $350.71. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company's quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.44) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in ALNY. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $27,000. Golden State Wealth Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Finally, Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $32,000. 92.97% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ALNY has been the subject of several recent research reports. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, May 2nd. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an "equal weight" rating in a report on Friday, May 1st. Chardan Capital restated a "buy" rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. HC Wainwright restated a "buy" rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 5th. Finally, Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $463.13.
View Our Latest Stock Report on Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
